Lipocine Inc. (LPCN) Stock Forecast & Analysis

Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Lipocine Inc. (LPCN:NASDAQ), powered by AI.

Current Price
$2.26
P/E Ratio
-1.3
Market Cap
12M
Sector
Healthcare
What is the Lipocine Inc. stock price forecast?

Lipocine Inc. is currently trading at $2.26. View real-time AI analysis on Alpha Lenz.

What is Lipocine Inc. insider trading activity?

View the latest insider trading data for Lipocine Inc. on Alpha Lenz.

What is Lipocine Inc.'s P/E ratio?

Lipocine Inc.'s P/E ratio is -1.3.

Lipocine Inc.

NASDAQ · LPCN
$2.26+0.06(+2.73%)Pre-marketNASDAQ regular session 09:30–16:00 ET
Ask about Lipocine Inc.'s future dividend policy...
Alpha Chat Insight

Lipocine Inc. trades at a P/E of -1.3 (undervalued) with modest ROE of -54.3%. 3Y revenue CAGR of 58.1% highlights clear growth momentum.

Ask for details

Company Overview

Lipocine Inc. is a pharmaceutical company specializing in the development and commercialization of innovative products through its proprietary oral drug delivery technology. The primary function of Lipocine Inc. is to improve patient compliance by converting drugs traditionally administered via injection into oral dosage forms. This technology enhances the absorption and bioavailability of oral medications, thereby addressing common challenges faced in drug delivery. Lipocine Inc.'s portfolio includes products targeting testosterone deficiency and metabolic disorders, with some in advanced stages of clinical trials. Operating at the intersection of the pharmaceutical and biotechnology sectors, the company plays a vital role in advancing therapeutic solutions for endocrine and metabolic ailments. Lipocine's innovations hold significant market potential, as they aim to create more patient-friendly therapeutic options, which can lead to increased adoption and market acceptance. Headquartered in Salt Lake City, Utah, Lipocine Inc. continues to explore strategic partnerships to expand its reach and impact within the healthcare industry.

CEODr. Mahesh V. Patel Ph.D.
SectorHealthcare
IndustryBiotechnology
Employees16

Company Statistics

FY 2025

Profile

$12.31MMarket Cap
$1.98MRevenue
0.00Shares Out
16Employees

Margins

-334.26%Gross
-521.61%EBITDA
-524.69%Operating
-487.04%Pre-Tax
-487.06%Net

Valuation

-1.28P/E
0.85P/B
6.23EV/Sales
-0.69EV/EBITDA
-1.26P/FCF

Growth (CAGR)

58.12%Rev 3Yr
N/ARev 5Yr
N/AOp Inc 3Yr
N/AOp Inc 5Yr
N/ANet Inc 3Yr
N/ANet Inc 5Yr

Returns

-48.73%ROA
-54.28%ROE
-52.49%ROIC

Financial Health

$5.21MCash & Cash Equivalents
$-2.68MNet Debt
17.46%Debt/Equity
N/AInterest Cov

Frequently Asked Questions

Lipocine Inc. (ticker: LPCN) is a company listed on NASDAQ in the Healthcare sector (Biotechnology). It has approximately 16 employees. Market cap is $12M.

The current price is $2.26 with a P/E ratio of -1.28x and P/B of 0.85x.

ROE is -54.28% and operating margin is -524.69%. Annual revenue is $2M.

Alpha Lenz
Singapore
Treasurer Pte Ltd | License: 202346277E
9 Straits View Marina One West Tower #05-07 Singapore 018937
contact@treasurer.co.kr
©2026 Treasurer Pte Ltd. All rights reserved.
Lipocine Inc. (LPCN) Stock Forecast 2026 $2.26 — Price, Financials & Analyst Targets | Alpha Lenz